For example, the CellSearch® system uses nanoparticles labeled with antibodies that target the epithelial cell adhesion molecule (EpCAM) to separate CTC from other cells present in the blood of patients with metastatic colorectal, breast, or prostate cancer. This evidence concerns the gene EPCAM and prostate carcinoma.